GlassScriptPhysician profile
Joshua B Shipley
NPI 1104822436
$3,025.20
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,270 · 2021: $109.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $366.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $350.22 | 2019-2020 | |
| Amarin Pharma, INC. | $314.02 | 2019-2020 | |
| Novo Nordisk INC | $308.07 | 2019-2020 | |
| Pfizer INC. | $276.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $184.46 | 2019-2020 | |
| Daiichi Sankyo INC. | $142.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $117.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.63 | 2019-2020 | |
| Lilly USA, LLC | $79.18 | 2019-2020 | |
| Bausch Health US, LLC | $68.33 | 2020-2021 | |
| Edwards Lifesciences Corporation | $66.56 | 2021 | |
| Sanofi Pasteur INC. | $54.40 | 2019 | |
| Eisai INC. | $50.08 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $50.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $44.59 | 2019 | |
| Abbott Laboratories | $41.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $40.81 | 2019 | |
| Seqirus USA INC | $36.32 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $35.56 | 2019 | |
| Allergan, INC. | $35.00 | 2019 | |
| Bioventus LLC | $24.58 | 2020 | |
| Vivus LLC | $19.94 | 2020 | |
| Vertiflex, INC. | $19.19 | 2019 | |
| Esperion Therapeutics, INC. | $17.06 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.44 | 2019 | |
| Genentech USA, INC. | $15.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.60 | 2019 | |
| Astellas Pharma US INC | $13.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Shipley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.